The origins of cardiopulmonary bypass

It is obvious that any operative procedure upon the heart could be performed better if that organ were temporarily relieved of its function of pumping blood. For example, if the flow of blood through the heart and lungs could be safely stopped for 30 minutes, it is conceivable that a new field of cardiac surgery might be developed. In order to maintain life during such a temporary cessation of blood flow through the heart and lungs, it is necessary to assume the function of these organs by some other means.
John H. Gibbon Jr, 1939 1 The introduction of cardiopulmonary bypass (CPB) in the 1950s revolutionised the scope and practice of cardiac surgery. Yet the concepts of extracorporeal oxygenation and circulatory support, and many of the scientific and technological advances necessary for their realisation, originated several decades earlier.
During the early 1800s, Julien Le Gallois, adjunct member of the Society of Professors of the Faculty of Medicine of Paris, undertook a series of experiments in which he aimed to identify the parts of the brain and the body that were essential for life. Publishing his results in 1812, Le Gallois noted: "But if the place of the heart could be supplied by injection-and if, for the regular continuance of this injection, there could be furnished a quantity of arterial blood, whether natural, or artificially formed, supposing such a formation possible, -then life might be indefinitely maintained" 2 .
Physiologists subsequently turned their attention to the perfusion of isolated organs. In the 1850s, the discovery that whisking blood in the presence of room air resulted not only in its defibrination (thus preventing clotting), but also some degree of oxygenation, allowed Charles-Édouard BrownSéquard to elicit reflex muscular responses when he injected it into arteries supplying the amputated body parts of dogs, as well as humans, who had been guillotined 3 .
A decade later, Carl Ludwig and Alexander Schmidt devised a simple gravity-driven system for organ perfusion. Defibrinated blood was arterialised by shaking it together with air in a balloon, and then added to an elevated reservoir 4 .
The 1880s saw the introduction of more sophisticated methods for the extracorporeal oxygenation of blood. In 1882, Waldermar von Schröder bubbled oxygen through a trough of venous blood 5 . Although this proved effective, von Schröder's technique was limited by the concomitant production of foam. Soon after, at the University of Leipzig, Max von Frey and Max Gruber developed the rotating film oxygenator 6 . This comprised a slanted glass cylinder, into the top of which venous blood was introduced. As the cylinder rotated at 30 rpm, a thin film of blood spread over its inner surface, where it came into contact with oxygen, and gas exchange took place. In 1885, von Frey and Gruber described the use of this oxygenator as part of a closed circuit for continuous organ perfusion 6 . Their remarkably sophisticated machine included heating and cooling chambers, in addition to valves and motor-driven syringe pumps, which maintained the flow of blood.
Believing this equipment to be too complicated, other researchers oxygenated venous blood using isolated animal lungs, ventilated with bellows 7 . While further pumps, oxygenators and perfusion circuits were introduced for use with defibrinated, hirudinated and citrated blood during the late 19th and early 20th century [8] [9] [10] [11] , the clinical utility of this technology was yet to be recognised.
Serving as a doctor in the Russian army during the First World War, Sergei Brukhonenko witnessed several deaths due to cardiothoracic injuries. Realising that CPB might have allowed these wounds to be repaired, he went on to develop a prototype machine, known as the 'autojector' 12 . This included two mechanically operated diaphragm pumps and a system of valves. An isolated animal lung served as an oxygenator, and the addition of suramin (an anti-trypanosomal medication with anticoagulant effects) prevented clotting. The machine was first utilised to perfuse the isolated heads of dogs 13 , and then on 1 November 1926, Brukhonenko began a series of experiments in which he successfully bypassed the hearts and lungs of animals 14 . Over the next ten years in Moscow, Nikolai Terebinski performed several hundred open-heart procedures on dogs, with the assistance of the autojector 15 . His work was largely unknown outside of the Soviet Union.
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In February 1931, John Gibbon Jr, surgical research fellow at Massachusetts General Hospital, encountered a woman who had developed a massive pulmonary embolus following a cholecystectomy 15 days previously 16 . First described in 1908 17 , Trendelenburg's procedure for open pulmonary embolectomy was associated with an extremely high mortality, and it was therefore decided to operate only if the patient became moribund. Gibbon stayed by her bedside and later recorded: "During that long night, helplessly watching the patient struggle for life, the idea naturally occurred to me that if it were possible to remove continuously some of the blue blood from the patient's distended veins, put oxygen into that blood and allow carbon dioxide to escape from it, and then inject continuously the now red blood back into the patient's arteries, we might have been able to save her life" 16 . At 8 am the following morning the patient suffered a cardiac arrest. Despite rapid perimortem retrieval of the clot, she died.
Three years later, Gibbon started to construct a CPB machine that could maintain life during partial or complete occlusion of the main pulmonary artery 18 . He later acknowledged that such a device might also facilitate surgery on the heart, under direct vision 1 . Gibbon's early design 18 utilised a rotating film oxygenator (which was sufficient to oxygenate a cat), and a modified version of an existing pneumatic perfusion pump [18] [19] [20] . Heparin had recently become available commercially, and was employed as an anticoagulant 16 . In 1937, he reported that: "normal circulation and respiration can be spontaneously re-established and maintained for several hours after a 30 minute period of complete occlusion of the pulmonary artery" 18 . Gibbon subsequently modified his device to include roller pumps 1 , and in 1939, described the prolonged survival of cats "which were normal in every respect and exhibited no neurological changes" 1 after periods of pulmonary artery clamping.
Following the Second World War, Gibbon obtained the assistance of engineers from the International Business Machines (IBM) Corporation, who helped develop a machine "large enough and efficient enough to be used on human patients" 16 . By the early 1950s the device was deemed suitable for clinical use, and on 6 May 1953, Gibbon performed the world's first successful open-heart procedure using CPB, closing a large atrial septal defect in an 18-year-old girl. 
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